Clinical Trial Update: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating JNJ-73763989 with pegylated interferon alpha-2a, and a nucleos(t)ide analog, with or without JNJ-56136379, in treatment-naive HBeAg-pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-56136379
• JNJ-73763989
• Nucleos(t)ide analog
• Pegylated Interferon Alpha-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19